In an article in the current edition of Cell Stem Cell, ASHBi researcher David Cyranoski and colleagues in Japan and Australia find that Japan’s revised pharmaceutical act has led to the marketing of cellular therapies with questionable safety and efficacy.

Paper Information

Cyranoski, D., Sipp, D., Mallik, S. and Rasko. J. (2023) Too little, too soon: Japan’s experiment in regenerative medicine deregulation. Cell Stem Cell. 30, 913-916, DOI: 10.1016/j.stem.2023.06.005.